Tozman E C
University of Miami School of Medicine, Florida.
Curr Opin Rheumatol. 1992 Feb;4(1):81-3.
Recent literature on nonneoplastic hematologic disease in the rheumatic disorders has been reviewed, and current concepts on the anemia of rheumatoid arthritis and its treatment have been expanded. The anemia of chronic renal failure and of acquired immunodeficiency syndrome has responded to treatment with recombinant human erythropoietin. Recent studies document that the anemia of rheumatoid disease can also be alleviated with intermittent intravenous or subcutaneous administration of erythropoietin without apparent adverse reaction. However, no improvement is evident in the underlying rheumatoid disease or functional abilities of these patients. Further data are needed to determine the utility of erythropoietin therapy in rheumatoid arthritis and in other rheumatic diseases. Other mechanisms of anemia of rheumatoid disease have been studied, and as the underlying defects become known, other therapies may become available to patients with rheumatoid arthritis and other rheumatic diseases.
对近期有关风湿性疾病中非肿瘤性血液系统疾病的文献进行了综述，并扩展了目前关于类风湿关节炎贫血及其治疗的概念。慢性肾衰竭和获得性免疫缺陷综合征的贫血对重组人促红细胞生成素治疗有反应。近期研究表明，类风湿病贫血也可通过间歇性静脉内或皮下注射促红细胞生成素得到缓解，且无明显不良反应。然而，这些患者的潜在类风湿病或功能能力并无明显改善。需要更多数据来确定促红细胞生成素疗法在类风湿关节炎和其他风湿性疾病中的效用。类风湿病贫血的其他机制也已得到研究，随着潜在缺陷逐渐明了，类风湿关节炎和其他风湿性疾病患者可能会有其他治疗方法可用。
